Nova Leap Health (NLH) AI Stock Analysis

• Market Cap: C$27.94M
• Dividend Yield: N/A
• Average Volume (3M): 21.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: 19.61%
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): >-0.01
• Shares Outstanding: 87,314,255
• 10 Day Avg. Volume: 17,344
• 30 Day Avg. Volume: 21,452
• PEG Ratio: 0.81
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 0.56
• P/FCF Ratio: 12.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: C$0.37 ▲(31.07% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is driven primarily by mixed financial performance—stronger solvency and positive (but softening) cash generation offset by volatile profitability and a 2025 net loss. Technicals add support as the stock is trading above key moving averages with positive MACD. Valuation is a headwind because earnings are negative (P/E not meaningful) and no dividend yield is available.

Positive Factors

Recurring home-care service model

The core business is recurring, hourly non-medical home care delivered directly to clients. That service-based, demand-driven model creates predictable revenue streams tied to ongoing care needs, supporting stable utilization and cash generation over multiple quarters to years.

Sustained revenue expansion

Consistent top-line growth over the multi-year period shows the company can expand scale, likely via organic demand and acquisitions. Returning to positive YoY revenue growth in 2025 demonstrates resiliency in demand and supports longer-term capacity to fund operations and strategic investments.

Conservative leverage profile

Low leverage provides financial flexibility for acquisitions, working capital, or downturns without high insolvency risk. A conservatively levered balance sheet supports durable capital allocation choices and lowers financing cost sensitivity across 2–6 month horizons and beyond.

Negative Factors

Profitability volatility

Earnings have swung materially year-to-year, culminating in a net loss in 2025. This volatility signals inconsistent operating execution or integration issues from acquisitions, reducing predictability of retained earnings and limiting reliable internal funding for growth or reserves.

Compressed operating margins

Sustained margin compression weakens the company's ability to convert revenue into sustainable profits and free cash. Lower operating leverage means revenue gains produce smaller incremental profits, constraining reinvestment and making earnings more sensitive to cost inflation or pricing pressure.

Declining free cash flow

A downward trend in free cash flow reduces internal funding for acquisitions, working capital, and margin-improvement initiatives. Even though FCF stays positive, the decline limits strategic optionality and increases reliance on external financing for growth or to smooth earnings variability.

Nova Leap Health Business Overview & Revenue Model

Company Description

Nova Leap Health Corp. provides home and home health care services in the United States and Canada. Its services include dementia care, companionship, personal and respite care, cooking and meal preparation, bathing, dressing, grooming, housekeeping, errands, transportation, and medication reminders by nursing staff. Nova Leap Health Corp. was incorporated in 2015 and is headquartered in Halifax, Canada.

How the Company Makes Money

Nova Leap Health generates revenue through its home health care services by charging clients for the hours of care provided. The company typically operates on a fee-for-service model, where clients are billed based on the specific services rendered. Key revenue streams include personal care services, which may involve assistance with daily living activities, and specialized care for clients with specific health needs. NLH also benefits from partnerships with healthcare providers and insurance companies, which can facilitate client referrals and enhance service offerings. Additionally, the company may explore opportunities for government contracts or funding programs aimed at supporting home health care services, contributing further to its earnings.

Nova Leap Health Financial Statement Overview

Summary

Financials are mixed. Revenue has grown over time and returned to YoY growth in 2025, and the balance sheet is conservatively levered (low debt-to-equity). However, profitability is inconsistent with a return to a small net loss in 2025 and compressed operating margins, while free cash flow remained positive but declined in 2025.

Income Statement

Revenue has expanded over the period (from ~17.3M in 2020 to ~32.0M in 2025), and 2025 returned to growth (+6.9% YoY) after a mixed 2023–2024. Profitability, however, has been inconsistent: 2025 slipped to a small net loss (about -0.6% margin) versus a solid profit in 2024 (~5.4% margin), and operating profitability has compressed materially from 2021 highs to mid-single-digit levels in 2025. Gross margin has been relatively steady in the mid-to-high 30% range, but the weaker operating leverage and earnings volatility weigh on the score.

Balance Sheet

The balance sheet appears conservatively levered, with low debt relative to equity in recent years (debt-to-equity ~0.15 in 2025, down significantly from 2020 levels). Equity has remained substantial and has grown versus 2020, supporting financial flexibility. The main weakness is return on equity volatility—positive in 2024 but negative in 2025—indicating that while leverage risk is modest, shareholder returns are not consistently strong.

Cash Flow

Cash generation is positive and fairly steady, with operating cash flow and free cash flow remaining positive each year shown (about 1.4M free cash flow in 2025). That said, free cash flow declined in 2025 (about -11% YoY), and cash-flow-to-revenue levels are not particularly high. A positive point is that cash flow has generally tracked reported earnings reasonably well across the period, but the recent downtrend in free cash flow limits the score.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	32.02M	25.76M	26.18M	28.21M	21.28M
Gross Profit	11.85M	9.89M	9.77M	9.98M	7.21M
EBITDA	1.97M	2.50M	994.47K	420.35K	4.76M
Net Income	-193.19K	1.38M	-1.05M	-835.75K	1.76M
Balance Sheet
Total Assets	23.44M	22.39M	20.90M	23.95M	26.77M
Cash, Cash Equivalents and Short-Term Investments	1.49M	1.40M	894.76K	1.27M	1.73M
Total Debt	2.93M	2.53M	1.40M	3.97M	6.20M
Total Liabilities	4.43M	4.14M	2.70M	5.27M	8.29M
Stockholders Equity	19.01M	18.25M	18.20M	18.68M	18.48M
Cash Flow
Free Cash Flow	1.42M	1.36M	2.13M	949.49K	2.18M
Operating Cash Flow	1.42M	1.39M	2.15M	1.02M	2.18M
Investing Cash Flow	-1.26M	-1.59M	-23.13K	-56.24K	-7.40M
Financing Cash Flow	-86.91K	729.78K	-2.52M	-1.41M	4.33M

Nova Leap Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Positive. The current price of 0.28 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.31, and below the 200-day MA of 0.30, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.37 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NLH.

Nova Leap Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXE	70 Outperform	C$2.56B	18.86	47.65%	2.28%	11.59%	41.99%
DR	67 Neutral	C$310.02M	10.68	89.16%	2.35%	-40.05%	558.77%
CRRX	66 Neutral	C$232.75M	9.17	28.24%	1.03%	0.19%	―
NLH	63 Neutral	C$27.94M	-92.15	4.10%	―	19.61%	―
SIA	63 Neutral	C$2.30B	42.05	6.93%	4.47%	11.47%	6.45%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
PHA	46 Neutral	C$1.11M	-0.14	202.02%	―	-22.61%	7.72%

Nova Leap Health Corporate Events

Nova Leap Posts Record 2025 Results as It Expands Into Broader Community-Based Care

Nova Leap Health reported its strongest year on record in 2025, with consolidated revenue rising 22.2% to $31.5 million and adjusted EBITDA up 31.0% to $2.05 million, achieved while keeping leverage low and without issuing new equity since 2022. Management emphasized a deliberate growth strategy centered on cash flow and balance sheet strength, highlighting that recent performance has enhanced the company’s financial profile and supported per-share value creation.

Beyond the numbers, the company is repositioning from a pure home care provider to a broader community-based care organization organized around four complementary pillars: home care, care management, palliative care and forthcoming private nursing. New care management and palliative care divisions, along with the planned launch of private nursing in 2027 and targeted investment in clinically rich markets and existing regions, are intended to expand Nova Leap’s role across the continuum of care and improve both growth prospects and operating efficiency amid rising demand for home and community services.

The most recent analyst rating on (TSE:NLH) stock is a Hold with a C$0.31 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.

Nova Leap Health Expands Into Palliative Home Care With New Nova Scotia Division

Nova Leap Health Corp. has launched a dedicated palliative care division in Nova Scotia through its subsidiary Earth Angels Home Care, expanding its presence along the continuum of care for individuals with life-limiting illnesses. The new division will provide nursing-led in-home symptom management, coordinated support with families and healthcare teams, and staff training aligned with national palliative care standards, addressing rising demand for home-based end-of-life support in an aging population and strengthening Nova Leap’s positioning as a key home care provider in Canada, with potential to replicate the model in other provinces over time.

The most recent analyst rating on (TSE:NLH) stock is a Hold with a C$0.31 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.

Nova Leap Elevates Melissa Anderson to Senior Vice President as U.S. Expansion Accelerates

Nova Leap Health Corp. has promoted Melissa Anderson from Vice President, Operations (U.S.) to Senior Vice President (U.S.), effective January 1, 2026, reflecting her central role in enhancing the company’s U.S. operations through operational improvements, leadership development and EBITDA growth. In her expanded role, Anderson will oversee U.S. home care operations, including strategic planning, performance, expansion into new states, and integration of new service lines such as the recently launched Care Management division, a move that underscores Nova Leap’s continued expansion across the United States and Canada through targeted acquisitions and de novo growth supported by scalable infrastructure.

The most recent analyst rating on (TSE:NLH) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.

Nova Leap Health Corp. Launches Care Management Division in the U.S.

Nova Leap Health Corp. has announced the launch of a new Care Management division in the United States, aiming to enhance care delivery and outcomes across the healthcare continuum. Led by Breanne Muchemore, the division will initially focus on the Massachusetts market, offering services such as care coordination, dementia navigation, and transitional care management. This strategic expansion is expected to broaden Nova Leap’s role in the care continuum, deepen client and partner relationships, and create new revenue streams, contributing to the company’s long-term growth strategy.

The most recent analyst rating on (TSE:NLH) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.

Nova Leap Health Corp. Issues Stock Options to Key Personnel

Nova Leap Health Corp., a prominent player in the home health care industry, has announced the issuance of 950,000 stock options to its directors, officers, and senior employees. This strategic move, under the company’s Equity Incentive Plan, is likely to enhance employee engagement and align interests with shareholders, potentially impacting the company’s growth trajectory and market positioning positively.

The most recent analyst rating on (TSE:NLH) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.